ALK and pneumonitis: Pulmonary toxicities requiring treatment termination, including interstitial lung disease, pneumonitis, and pulmonary fibrosis, are also relatively rare, occurring in approximately 0.2%–10.9% of the total patients with ALK+ mNSCLC (7).